• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes.专家建议使用时间范围内和其他连续血糖监测指标,以实现糖尿病患者以患者为中心的血糖控制。
J Diabetes Sci Technol. 2023 Sep;17(5):1326-1336. doi: 10.1177/19322968221088601. Epub 2022 Apr 26.
2
Time in Range from Continuous Glucose Monitoring: A Novel Metric for Glycemic Control.连续血糖监测的时间范围:一种新的血糖控制衡量指标。
Diabetes Metab J. 2020 Dec;44(6):828-839. doi: 10.4093/dmj.2020.0257. Epub 2020 Dec 23.
3
THE ADDED AND INTERPRETATIVE VALUE OF CGM-DERIVED PARAMETERS IN TYPE 1 DIABETES DEPENDS ON THE LEVEL OF GLYCEMIC CONTROL.CGM 衍生参数在 1 型糖尿病中的附加和解释价值取决于血糖控制水平。
Endocr Pract. 2021 Jan;27(1):44-50. doi: 10.4158/EP-2020-0293. Epub 2020 Nov 18.
4
Making sense of glucose metrics in diabetes: linkage between postprandial glucose (PPG), time in range (TIR) & hemoglobin A1c (A1C).解析糖尿病中的葡萄糖指标:餐后血糖(PPG)、达标时间(TIR)和糖化血红蛋白(HbA1c)之间的关联。
Postgrad Med. 2021 Apr;133(3):253-264. doi: 10.1080/00325481.2020.1851946. Epub 2020 Dec 14.
5
Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy.连续血糖监测指标(平均血糖、血糖超标时间和血糖达标时间)优于糖化血红蛋白,可用于评估治疗效果。
Diabetes Obes Metab. 2023 Feb;25(2):596-601. doi: 10.1111/dom.14906. Epub 2022 Dec 1.
6
Expert Panel Recommendations for Use of Standardized Glucose Reporting System Based on Standardized Glucometrics Plus Visual Ambulatory Glucose Profile (AGP) Data in Clinical Practice.专家小组建议在临床实践中使用基于标准化血糖指标和可视化动态血糖图谱(AGP)数据的标准化血糖报告系统。
Front Endocrinol (Lausanne). 2022 Jan 24;12:663222. doi: 10.3389/fendo.2021.663222. eCollection 2021.
7
Can the Use of Continuous Glucose Monitoring Improve Glycemic Control in Patients with Type 1 and 2 Diabetes Receiving Dialysis?对于接受透析治疗的1型和2型糖尿病患者,使用持续葡萄糖监测能否改善血糖控制?
Nephron. 2023;147(2):91-96. doi: 10.1159/000525676. Epub 2022 Jul 13.
8
Time-in-range for monitoring glucose control: Is it time for a change?监测血糖控制的时间范围:是时候改变了吗?
Diabetes Res Clin Pract. 2021 Jul;177:108917. doi: 10.1016/j.diabres.2021.108917. Epub 2021 Jun 11.
9
Comparing the effectiveness of continuous subcutaneous insulin infusion with multiple daily insulin injection for patients with type 1 diabetes mellitus evaluated by retrospective continuous glucose monitoring: A real-world data analysis.通过回顾性连续血糖监测评估连续皮下胰岛素输注与多次胰岛素皮下注射治疗 1 型糖尿病患者的疗效比较:真实世界数据分析。
Front Public Health. 2022 Aug 25;10:990281. doi: 10.3389/fpubh.2022.990281. eCollection 2022.
10
Clinical Recommendations for the Use of the Ambulatory Glucose Profile in Diabetes Care.临床推荐在糖尿病护理中使用动态血糖监测。
J Diabetes Sci Technol. 2020 May;14(3):586-594. doi: 10.1177/1932296819883032. Epub 2019 Nov 13.

引用本文的文献

1
Validation of a predictive calculator for optimal glycemic control and time-in-tight-range following CGM sensor placement in type 1 diabetes and pancreatic diabetes: a prospective study.1型糖尿病和胰腺性糖尿病患者在连续血糖监测(CGM)传感器置入后用于优化血糖控制和血糖处于目标范围内时间的预测计算器的验证:一项前瞻性研究。
Endocrine. 2025 Aug 26. doi: 10.1007/s12020-025-04385-7.
2
Daytime and nighttime glycemic control with control-IQ technology vs. standard therapy in type 1 diabetes: a systematic review and meta-analysis with trial sequential analysis and GRADE assessment.1型糖尿病中使用Control-IQ技术与标准疗法进行日间和夜间血糖控制:一项采用试验序贯分析和GRADE评估的系统评价和荟萃分析
Diabetol Metab Syndr. 2025 Aug 12;17(1):325. doi: 10.1186/s13098-025-01906-2.
3
Proposed Practical Guidelines to Improve Glycaemic Management by Reducing Glycaemic Variability in People with Type 1 Diabetes Mellitus.通过降低1型糖尿病患者的血糖变异性来改善血糖管理的实用指南建议
Diabetes Ther. 2025 Apr;16(4):569-589. doi: 10.1007/s13300-025-01703-0. Epub 2025 Feb 28.
4
Smart Insulin Pen in Pregnant Women with Type 1 Diabetes: An Encouraging Case Series.1型糖尿病孕妇使用智能胰岛素笔:一个令人鼓舞的病例系列
Healthcare (Basel). 2024 Dec 29;13(1):38. doi: 10.3390/healthcare13010038.
5
Time Below Range and Its Influence on Hypoglycemia Awareness and Severe Hypoglycemia: Insights From the Association of British Clinical Diabetologists Study.低于目标范围的时间及其对低血糖感知和严重低血糖的影响:来自英国临床糖尿病学家协会研究的见解
Diabetes Care. 2025 Mar 1;48(3):437-443. doi: 10.2337/dc24-1833.
6
Predicting Time in Range Without Hypoglycaemia Using a Risk Calculator for Intermittently Scanned CGM in Type 1 Diabetes.使用1型糖尿病间歇性扫描式动态血糖监测风险计算器预测无低血糖的血糖达标时间
Endocrinol Diabetes Metab. 2025 Jan;8(1):e70020. doi: 10.1002/edm2.70020.
7
Exploring the Continuous Glucose Monitoring in Pediatric Diabetes: Current Practices, Innovative Metrics, and Future Implications.探索儿童糖尿病的持续葡萄糖监测:当前实践、创新指标及未来影响
Children (Basel). 2024 Jul 27;11(8):907. doi: 10.3390/children11080907.
8
Impact of Continuous Glucose Monitoring and its Glucometrics in Clinical Practice in Spain and Future Perspectives: A Narrative Review.西班牙临床实践中连续血糖监测及其血糖指标的影响和未来展望:叙述性综述。
Adv Ther. 2024 Sep;41(9):3471-3488. doi: 10.1007/s12325-024-02943-5. Epub 2024 Aug 2.
9
Current landscape and comprehensive management of glycemic variability in diabetic retinopathy.糖尿病视网膜病变中血糖变异性的现状及综合管理。
J Transl Med. 2024 Jul 29;22(1):700. doi: 10.1186/s12967-024-05516-w.
10
A moderately higher time-in-range threshold improves the prognosis of type 2 diabetes patients complicated with COVID-19.适度提高血糖在目标范围内的阈值可改善2型糖尿病合并新型冠状病毒肺炎患者的预后。
Front Endocrinol (Lausanne). 2024 Jul 2;15:1353838. doi: 10.3389/fendo.2024.1353838. eCollection 2024.

本文引用的文献

1
16. Diabetes Care in the Hospital: Standards of Medical Care in Diabetes-2022.16. 医院中的糖尿病护理:《糖尿病医学诊疗标准-2022》。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S244-S253. doi: 10.2337/dc22-S016.
2
7. Diabetes Technology: Standards of Medical Care in Diabetes-2022.7. 糖尿病技术:《2022 年糖尿病医学诊疗标准》。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S97-S112. doi: 10.2337/dc22-S007.
3
6. Glycemic Targets: Standards of Medical Care in Diabetes-2022.6. 血糖目标:2022 年糖尿病医学护理标准。
Diabetes Care. 2022 Jan 1;45(Suppl 1):S83-S96. doi: 10.2337/dc22-S006.
4
Reliability of Inpatient CGM: Comparison to Standard of Care.住院患者连续血糖监测的可靠性:与常规护理的比较。
J Diabetes Sci Technol. 2023 Mar;17(2):329-335. doi: 10.1177/19322968211062168. Epub 2021 Dec 15.
5
Good Metabolic Control in Children with Type 1 Diabetes Mellitus: Does Glycated Hemoglobin Correlate with Interstitial Glucose Monitoring Using FreeStyle Libre?1型糖尿病患儿的良好代谢控制:糖化血红蛋白与使用FreeStyle Libre进行的组织间液葡萄糖监测是否相关?
J Clin Med. 2021 Oct 24;10(21):4913. doi: 10.3390/jcm10214913.
6
Continuous Glucose Monitoring and Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin-Reply.基础胰岛素治疗的2型糖尿病患者的连续血糖监测与血糖控制——回复
JAMA. 2021 Oct 5;326(13):1330-1331. doi: 10.1001/jama.2021.13478.
7
Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus: a systematic review and meta-analysis of randomized clinical trials.连续血糖监测在妊娠期糖尿病母婴结局中的疗效:随机临床试验的系统评价和荟萃分析。
Diabet Med. 2022 Jan;39(1):e14703. doi: 10.1111/dme.14703. Epub 2021 Oct 13.
8
The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes.1型糖尿病强化治疗早期与晚期实施的有益效果
Diabetes Care. 2021 Aug 11;44(10):2225-30. doi: 10.2337/dc21-1331.
9
The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study.加拿大使用基础胰岛素治疗 2 型糖尿病中,瞬感葡萄糖监测对糖化血红蛋白的影响:一项回顾性真实世界图表审查研究。
Diab Vasc Dis Res. 2021 Jul-Aug;18(4):14791641211021374. doi: 10.1177/14791641211021374.
10
Relationships between HbA1c and continuous glucose monitoring metrics of glycaemic control and glucose variability in a large cohort of children and adolescents with type 1 diabetes.在一个大型的 1 型糖尿病儿童和青少年队列中,HbA1c 与血糖控制和血糖变异性的连续血糖监测指标之间的关系。
Diabetes Res Clin Pract. 2021 Jul;177:108933. doi: 10.1016/j.diabres.2021.108933. Epub 2021 Jun 30.

专家建议使用时间范围内和其他连续血糖监测指标,以实现糖尿病患者以患者为中心的血糖控制。

Expert Recommendations for Using Time-in-Range and Other Continuous Glucose Monitoring Metrics to Achieve Patient-Centered Glycemic Control in People With Diabetes.

机构信息

Unidad de Gestión Clínica de Endocrinología y Nutrición, Hospital Universitario Virgen del Rocío, Sevilla, Spain.

Endocrinology and Nutrition Department, Health Sciences Research Institute and University, Hospital Germans Trias i Pujol, Badalona, Spain.

出版信息

J Diabetes Sci Technol. 2023 Sep;17(5):1326-1336. doi: 10.1177/19322968221088601. Epub 2022 Apr 26.

DOI:10.1177/19322968221088601
PMID:35470692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10563535/
Abstract

New metrics for assessing glycemic control beyond HbA1c have recently emerged due to the increasing use of continuous glucose monitoring (CGM) in diabetes clinical practice. Among them, time in range (TIR) has appeared as a simple and intuitive metric that correlates inversely with HbA1c and has also been newly linked to the risk of long-term diabetes complications. The International Consensus on Time in Range established a series of target glucose ranges (TIR, time below range and time above range) and recommendations for time spent within these ranges for different diabetes populations. These parameters should be evaluated together with the ambulatory glucose profile (AGP). Using standardized visual reporting may help people with diabetes and healthcare professionals in the evaluation of glucose control in frequent clinical situations. The objective of the present review is to provide practical insights to quick interpretation of patient-centered metrics based on flash glucose monitoring data, as well as showing some visual examples of common clinical situations and giving practical recommendations for their management.

摘要

由于连续血糖监测(CGM)在糖尿病临床实践中的广泛应用,目前已经出现了一些新的评估血糖控制的指标,不仅可以超越糖化血红蛋白(HbA1c)的评估。其中,血糖达标时间(TIR)作为一种简单直观的指标,与 HbA1c 呈负相关,并且与长期糖尿病并发症的风险也有新的关联。国际 TIR 共识制定了一系列目标血糖范围(TIR、血糖低于目标范围和血糖高于目标范围)和不同糖尿病人群的目标范围内时间的建议。这些参数应与动态血糖谱(AGP)一起评估。使用标准化的可视报告可能有助于糖尿病患者和医疗保健专业人员在频繁的临床情况下评估血糖控制情况。本综述的目的是为基于瞬态血糖监测数据的患者为中心指标的快速解读提供实用的见解,并展示一些常见临床情况的可视化示例,并给出管理这些情况的实用建议。